VIM and neoplasm: Further immunohistochemistry study demonstrated that PLX3397 + TMZ combined therapy significantly decreased cell proliferation (Ki-67), invasion (Vimentin), angiogenesis (CD31), and increased apoptosis (cleaved caspase-3) in G422TN-tumor compared to their monotherapy or Ctrl groups (Fig. 3I–P).